Glucose control and its implications for the general surgeon.

Am Surg

Department of Surgery, University of Louisville, Louisville, KY 40292, USA.

Published: November 2009

In the face of these conflicting data, how should the practicing surgeon approach the issue of tight glucose control in their critically ill surgical patients? The answer to that question may well change over time as new data emerge. For now, however, it seems reasonable to conclude that tight glucose control to the normal range (80-110 mg/dL) in critically ill general surgery patients (i.e., the Van den Berghe model) is an intriguing but unproven hypothesis that needs to be confirmed by prospective randomized trials in different ICUs and in a relevant patient population. It is quite possible, and probably likely, that levels of hyperglycemia that were previously thought to be inconsequential (180-200 mg/dL) may be harmful when sustained over prolonged periods of time and that better glucose control in the ICU than previously practiced is merited. However, given the detrimental effects of hypoglycemia, great care must be exercised in trying to achieve better glucose control so as not to induce harm. Technical considerations such as differences in glucose measuring systems, use of morning versus all glucose values, and nutritional regimens all need to be considered. The ICU is by definition a complex environment involving multiple teams of consulting specialists whose orders for medications, dialysis treatments, radiographic studies, and interruptions of enteral nutrition may all disrupt the ability to establish stable blood glucose levels. These factors need to be accounted for in daily clinical practice and their roles need to be better understood in future clinical trials. At present, it seems reasonable to attempt to control blood glucose levels in critically ill general surgery patients to moderate levels that avoid deleterious hypoglycemia but have been associated with encouraging clinical results until better data emerge. Until that time, the clinician will need to attempt to balance the potentially detrimental effects of hyperglycemia with the risk of hypoglycemia carefully until future trials involving general surgery patients are completed to clarify this issue.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3471562PMC

Publication Analysis

Top Keywords

glucose control
20
critically ill
12
general surgery
12
surgery patients
12
glucose
9
tight glucose
8
data emerge
8
ill general
8
better glucose
8
detrimental effects
8

Similar Publications

Potential trend of regenerative treatment for type I diabetes has been introduced for more than a decade. However, the technologies regarding insulin-producing cell (IPC) production and transplantation are still being developed. Here, we propose the potential IPC production protocol employing mouse gingival fibroblast-derived induced pluripotent stem cells (mGF-iPSCs) as a resource and the pre-clinical approved subcutaneous IPC transplantation platform for further clinical confirmation study.

View Article and Find Full Text PDF

Background: Diabetes mellitus is a growing global health issue, especially in low- and middle-income countries like Ethiopia. To the best of our knowledge, the impact of diabetes knowledge on glycemic control in Ethiopia has not been documented. This study assessed diabetes knowledge and its relationship with glycemic control among Type 2 diabetes (T2DM) patients in Debre Berhan, Ethiopia.

View Article and Find Full Text PDF

Purpose: Several studies suggest a linkage between PCOS and autoimmunity with a high frequency of chronic autoimmune thyroiditis (AIT) reported in PCOS patients, however, this subject remains controversial. The aim of this study was to investigate the prevalence of AIT in PCOS women and identify parameters that would serve as independent predictors of AIT.

Methods: Two hundred fifty seven (257) PCOS patients according to the NIH criteria and one hundred forty three (143) controls, women with normal menstrual cycles and without clinical or biochemical hyperandrogenism, were recruited for the study.

View Article and Find Full Text PDF

Cardiovascular Outcomes in Patients with Complex Type 2 Diabetes Mellitus Treated with the Dual SGLT Inhibitor Sotagliflozin: A Meta-analysis.

Diabetes Ther

January 2025

The State Key Laboratory Management and Control for Complex Systems, Institute of Automation, Chinese Academy of Sciences, Beijing, 100190, People's Republic of China.

Introduction: Scientific publications have shown sodium-glucose co-transporter-2 (SGLT2) inhibitors to have several beneficial effects in patients with complex type 2 diabetes mellitus (T2DM). However, sodium-glucose co-transporter-1 (SGLT-1) inhibitor is still under investigation in clinical trials. Recently, a dual inhibitor of sodium-glucose co-transporter (SGLT1/2), sotagliflozin, has been approved for use in patients with T2DM.

View Article and Find Full Text PDF

Turmeric is affected by various phytopathogens, which cause huge economic losses to farmers. In the present study, ten isolates of Pythium spp. were isolated from infected turmeric rhizomes and characterized.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!